Clinical trial · Observational
Glioblastoma Evaluation for Heterogeneity In RadioseNsitivity
Glioblastoma Evaluation for Heterogeneity In RadioseNsitivity (GEHIRN): Preclinical Observational Study on Ex-vivo Surgical Specimens
NCT05556382CI-TRIAL-00061287GEHIRNunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational study on GBM surgical samples to investigate if increasing doses of radiation therapy could improve the radiation response; and in particular the investigators will assess if there is a correlation between the number of the phosphorylated H2AX nuclear foci and the different dose level of radiation therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radiation of brain tissue specimen and dna damage analysis | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Determination of distribution of number of γH2AX foci in each irradiated specimen (Nfoci) for each radiation dose level
- timeFrame
- 1 month
- description
- Number of foci per irradiated sample (Nfoci) for each dose level expressed as \[(number of observed γH2AX foci per selected dose level)-(number of observed γH2AX foci in control unirradiated sample)\].
Secondary outcomes (1)
- measure
- correlation between n° of γH2AX foci and dose levels
- timeFrame
- 1 month
- description
- this correlation will be described by the slope for each sample Nfoci at increasing dose levels
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged \>18 years * Patients eligible for diagnostic or therapeutic surgical procedure * Written informed consent * Histopathologically confirmed newly diagnosed glioblastoma according to WHO 2021 * Availability of fresh tissue samples Exclusion Criteria: * Other extra-cranial cancer * Non GBM glioma * Previous brain radiation therapy
References
Publications (0)
Data not yet available
No reference posted for this study.